ArticleTherapeutic advances in neurological disorders2022
The importance of an early onset of migraine prevention: an evidence-based, hypothesis-driven scoping literature review.
Article in Therapeutic advances in neurological disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 15 citations in OpenAlex.
- Long-Term Improvements Following Initial Migraine Response in Eptinezumab-Treated Participants With Migraine for Whom 2-4 Prior Preventive Treatments Have Failed.European journal of neurology · 2026Trial
- Early Improvements With Atogepant for the Preventive Treatment of Migraine: Results From 3 Randomized Phase 3 Trials.Neurology · 2025Trial
- Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial.The journal of headache and pain · 2022Trial
- Post Hoc Analysis of Time to First and Sustained Improvement in Weekly Migraine Days Among Patients Receiving Preventive Treatment With Rimegepant 75 mg.Pain and therapy · 2026Article
- Calcitonin Gene-Related Peptide Monoclonal Antibody Utilization and Treatment Gaps in People with Migraine in Japan: Results from the OVERCOME (Japan) 2nd Study.Drugs - real world outcomes · 2026Article
- Long-Term Reductions in Headache Frequency, Severity, and Disability with Eptinezumab in Adults with Chronic Migraine: Results from the PREVAIL Trial.Pain and therapy · 2026Article
- Altered serum short-chain fatty acid profiles in episodic and chronic migraine and their modulation by preventive treatment.The journal of headache and pain · 2026Article
- Monthly Headaches and Severity in Patients on Galcanezumab or Traditional Preventive Migraine Medication: A 24-Month Claims and Electronic Health Records Study.Neurology and therapy · 2025Article
- Developmental trends in headache: an Italian school-based study of age- and gender-related changes in clinical characteristics and burden from childhood to adolescence.Therapeutic advances in neurological disorders · 2025Article
- Migraine symptoms, healthcare resources utilization and disease burden in a large Polish migraine cohort : Results from 'Migraine in Poland'-a nationwide cross-sectional survey.The journal of headache and pain · 2023Article
- Eptinezumab for the Prevention of Migraine: Clinical Utility, Patient Preferences and Selection - A Narrative Review.Therapeutics and clinical risk management · 2023Review
- Evaluating the efficacy of rimegepant as a preventive treatment for chronic and episodic migraine: a three-month longitudinal retrospective cohort study.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently approved migraine preventive therapies facilitate rapid control of migraine activity, potentially improving patients' lives and minimizing the societal burden of migraine. This review synthesizes available evidence on rates and timing of early onset of migraine prevention and identifies patient-level outcomes related to early onset prevention. This evidence-based scoping review identified all available clinical trial evidence regarding the early onset of prevention of migraine, under the hypothesis
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.